As part of Nectar Brands’ healthcare professional education, this article explores the role of medicinal cannabis within multimodal chronic pain management — particularly when patients are already prescribed other analgesic or psychotropic medications.
Chronic pain frequently involves polypharmacy. Patients may be prescribed NSAIDs, opioids, antidepressants, anticonvulsants, muscle relaxants, or sleep aids alongside other therapies. When considering the addition of medicinal cannabis, understanding potential pharmacodynamic and pharmacokinetic interactions is essential to support safe, individualised treatment planning.
This article outlines key interaction considerations and clinical principles for co-prescribing.
Chronic Pain and Polypharmacy
Chronic pain rarely exists in isolation. Patients commonly present with overlapping pain syndromes alongside comorbid psychiatric, inflammatory, or metabolic conditions. As a result, polypharmacy is common in chronic pain management.
Opioids, NSAIDs, antidepressants, anticonvulsants, muscle relaxants, and sedative-hypnotics are frequently prescribed in combination. This increases the risk of pharmacokinetic and pharmacodynamic interactions when introducing additional therapies, including medicinal cannabis.
Careful medication review and risk assessment are therefore essential when considering cannabinoid-based treatment.
Why Chronic Pain Management Is Clinically Complex
Chronic pain management is rarely straightforward. Heterogeneous aetiology, central sensitisation, comorbidity, and long-term pharmacotherapy all contribute to treatment complexity.
Several factors commonly complicate management:
Polypharmacy
Patients with chronic pain frequently present with comorbid conditions such as depression, anxiety disorders, sleep disturbance, cardiovascular disease, or metabolic disorders. As a result, concurrent prescribing of antidepressants, anticonvulsants, opioids, NSAIDs, benzodiazepines, or muscle relaxants is common. This increases the risk of pharmacokinetic interactions, additive sedation, and cumulative adverse effects.
Variable Pain Phenotypes
Chronic pain is not a single entity. Nociceptive, neuropathic, inflammatory, and centralised pain mechanisms may overlap within the same patient. Treatment response can therefore vary significantly between individuals.
Tolerance and Dose Escalation
Long-term use of opioids and certain other analgesics may lead to tolerance, dose escalation, and in some cases opioid-induced hyperalgesia. This can complicate symptom control and increase adverse effect burden.
Adverse Effects and Dependence Risk
Sedation, gastrointestinal effects, cardiovascular risk, endocrine effects, and dependency potential must all be considered when prescribing long-term pharmacotherapy.
Treatment Limitations
Not all patients respond adequately to first-line therapies. Multimodal approaches, incorporating pharmacological and non-pharmacological strategies, are often required to achieve meaningful functional improvement.
Given this complexity, any additional therapy, including medicinal cannabis, should be introduced within the context of a comprehensive medication review and risk assessment.
Common Pharmacological Classes in Chronic Pain Management
Chronic pain management commonly involves multiple pharmacological classes targeting distinct pain mechanisms. These may include:
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs inhibit cyclooxygenase (COX-1 and/or COX-2), reducing prostaglandin synthesis and peripheral inflammation. They are primarily used in nociceptive and inflammatory pain syndromes. Gastrointestinal, renal, and cardiovascular risk must be considered with long-term use.
Paracetamol (Acetaminophen)
Paracetamol acts centrally, likely via inhibition of central prostaglandin synthesis and modulation of serotonergic pathways. While widely used for mild-to-moderate pain, its efficacy in chronic pain is modest, and cumulative hepatotoxicity risk must be considered.
Opioids
Opioids exert analgesic effects via μ-opioid receptor agonism within the central nervous system. While effective for acute and cancer-related pain, long-term use in chronic non-cancer pain is associated with tolerance, dependence, endocrine effects, opioid-induced hyperalgesia, and respiratory depression. Sedative burden becomes particularly relevant in polypharmacy contexts.
Antidepressants
Tricyclic antidepressants (e.g. amitriptyline) and SNRIs (e.g. duloxetine) are commonly used in neuropathic and centralised pain states. Analgesic effects are mediated through modulation of descending inhibitory pathways via serotonin and noradrenaline reuptake inhibition.
Anticonvulsants
Gabapentinoids (gabapentin, pregabalin) reduce excitatory neurotransmission by binding to the α2δ subunit of voltage-gated calcium channels. They are commonly prescribed for neuropathic pain but contribute to cumulative sedation and dizziness, particularly when combined with opioids or other CNS depressants.
Muscle Relaxants
Agents such as baclofen (GABA-B agonist) and cyclobenzaprine act centrally to reduce muscle spasm but may increase sedation when combined with other centrally acting agents.
Topical Analgesics
Topical lidocaine (sodium channel blockade) and capsaicin (TRPV1 receptor desensitisation) provide localised analgesia with minimal systemic exposure.
Cannabinoid-Based Medicines
Cannabinoids (THC, CBD) interact with CB1 and CB2 receptors within the endocannabinoid system, influencing nociceptive processing, inflammatory pathways, and central pain modulation. Their role in chronic pain is typically as adjunct therapy, particularly in neuropathic or treatment-resistant presentations.
Medicinal Cannabis in Chronic Pain Management
Cannabinoid-based medicines exert their effects primarily through interaction with the endocannabinoid system, which plays a role in nociceptive processing, inflammation, and central pain modulation.
The two principal receptors, CB1 and CB2, are distributed throughout the central and peripheral nervous systems as well as immune tissues.
- CB1 receptors, predominantly located in the central nervous system, influence neurotransmitter release and pain signalling pathways.
- CB2 receptors, more commonly associated with immune cells and peripheral tissues, are involved in inflammatory modulation.
Δ9-tetrahydrocannabinol (THC) acts as a partial agonist at CB1 and CB2 receptors and contributes to analgesic and psychoactive effects. Cannabidiol (CBD) has more complex pharmacology, including indirect modulation of endocannabinoid tone, interaction with TRPV1 receptors, and potential anti-inflammatory effects.
In chronic pain, cannabinoids may influence both peripheral nociceptive pathways and central sensitisation mechanisms. Clinical evidence suggests benefit in selected chronic pain populations, particularly neuropathic pain, though treatment response is heterogeneous and effect sizes are generally modest.1
In practice, medicinal cannabis is most commonly considered as adjunctive therapy when first-line pharmacological strategies have provided insufficient relief or unacceptable adverse effects.
Can Medicinal Cannabis Interact with Other Pain Medications?
Cannabinoids may interact with other medications through both pharmacokinetic and pharmacodynamic mechanisms.
Pharmacokinetic interactions primarily relate to hepatic metabolism. Cannabidiol (CBD) is known to inhibit several cytochrome P450 enzymes, including CYP3A4, CYP2C19, and CYP2D6, which are involved in the metabolism of many commonly prescribed analgesic and psychotropic medications.2 Δ9-tetrahydrocannabinol (THC) is metabolised via CYP2C9 and CYP3A4 and may also contribute to interaction risk.3
Pharmacodynamic interactions most commonly involve additive central nervous system (CNS) depression, sedation, and impaired psychomotor function.
Key interaction considerations include:
NSAIDs
No major contraindications are established between cannabinoids and NSAIDs. However, theoretical metabolic interactions via CYP pathways have been proposed, and healthcare professionals should monitor for altered response or adverse effects, particularly in patients on high-dose or long-term NSAID therapy.
Paracetamol
No direct pharmacokinetic interaction is well established. However, as both CBD and paracetamol undergo hepatic metabolism, caution may be warranted in patients using high cumulative doses or with pre-existing hepatic impairment.
Opioids
Cannabinoids and opioids both exert central effects and may produce additive sedation. The combination increases the risk of CNS depression and may impair cognition, coordination, and respiratory drive, particularly in higher doses or in vulnerable populations.
While some observational data suggest potential opioid-sparing effects, evidence remains heterogeneous, and careful titration and monitoring are required when co-prescribing.4
Antidepressants
CBD may inhibit CYP2D6 and CYP2C19, potentially increasing serum concentrations of certain SSRIs, SNRIs, tricyclic antidepressants, and other centrally acting agents. Clinical impact varies and may include enhanced therapeutic or adverse effects. Monitoring is recommended when initiating or adjusting doses.
Anticonvulsants
CBD interacts with clobazam via CYP2C19 inhibition and has been associated with elevated liver enzymes when co-administered with valproate.5 Gabapentinoids are not significantly metabolised via CYP pathways; however, additive sedation may occur when combined with THC-containing products.
Benzodiazepines and Other Sedative-Hypnotics
THC-containing products may enhance sedative effects when combined with benzodiazepines or other hypnotics. Increased drowsiness, cognitive impairment, and falls risk should be considered.
Some observational studies report benzodiazepine reduction following medicinal cannabis initiation; however, evidence is limited and should not be interpreted as a primary indication for substitution
Muscle Relaxants
Additive CNS depression and motor impairment may occur when combined with cannabinoid-based medicines.
Topical Analgesics
Topical agents with minimal systemic absorption present negligible interaction risk.
Clinical Approach to Co-Prescribing
When considering the introduction of medicinal cannabis in a patient already receiving other analgesic or psychotropic therapies, a structured and individualised approach is recommended.
1. Conduct a Comprehensive Medication Review
Review all prescribed, over-the-counter, and complementary medications. Particular attention should be paid to:
- CNS depressants (e.g. opioids, benzodiazepines, gabapentinoids, sedative antidepressants)
- Medications metabolised via CYP3A4, CYP2C19, and CYP2D6 pathways
- Total sedative burden and polypharmacy risk
This helps identify potential pharmacokinetic interactions and additive pharmacodynamic effect before initiation.
2. Assess Hepatic and Clinical Risk Factors
As cannabinoids are hepatically metabolised, consider:
- Baseline liver function in patients with known hepatic impairment
Concurrent use of hepatically metabolised agents (e.g. high-dose paracetamol, valproate) - Alcohol use
Routine liver function monitoring may be appropriate in higher-risk patients.
3. Evaluate Sedation Burden and Falls Risk
Additive CNS depression is one of the most clinically relevant interaction risks.
Assess:
- Age
- Frailty
- Cognitive status
- Occupational requirements
- Existing sedating medications
Older adults and those on multiple CNS depressants may be particularly vulnerable to falls and impaired psychomotor function.
4. Initiate Low and Titrate Cautiously
Start at the lowest practical dose and titrate gradually according to symptom response and tolerability.
Where appropriate:
- Avoid simultaneous dose escalation of other sedating agents
- Reassess opioid or benzodiazepine dosing once cannabinoid response is established
Slow titration reduces adverse effect burden and improves tolerability.
5. Monitor and Reassess
Individual response to cannabinoids is variable.
Schedule follow-up to assess:
- Symptom response
- Adverse effects
- Functional outcomes
- Interaction-related concerns
Ongoing review ensures that medicinal cannabis remains appropriate within the broader treatment plan.
The Bottom Line
Chronic pain management frequently involves polypharmacy, multimodal strategies, and individual variability in treatment response. When introducing medicinal cannabis, clinicians must consider both pharmacokinetic interactions and additive pharmacodynamic effects — particularly sedation and hepatic metabolism.
Cannabinoid-based medicines may offer benefit in selected patients, most commonly as adjunctive therapy where conventional treatments have provided limited relief or unacceptable adverse effects. However, careful patient selection, dose titration, and ongoing monitoring are essential to minimise risk.
A structured medication review and clear counselling support safe integration within a broader pain management plan.
References
- 1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358.
- 2. Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos. 2021;49(12):1070-1080. doi:10.1124/dmd.121.000442
- 3. Nachnani R, Knehans A, Neighbors JD, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. Published 2024 May 22. doi:10.3389/fphar.2024.1282831
- 4. Nielsen S, Sabioni P, Trigo JM, et al. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 2017;42(9):1752-1765. doi:10.1038/npp.2017.51
- 5. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586-1592. doi:10.1111/epi.13852
